JNCI Journal of the National Cancer Institute最新文献_第6页

Development of a policy model for pediatric acute lymphoblastic leukemia to facilitate economic evaluation.

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-14 DOI: 10.1093/jnci/djaf024

Petros Pechlivanoglou, Linda Luu, Qing Li, J David Rios, Alexandra Moskalewicz, Sumit Gupta

{"title":"Development of a policy model for pediatric acute lymphoblastic leukemia to facilitate economic evaluation.","authors":"Petros Pechlivanoglou, Linda Luu, Qing Li, J David Rios, Alexandra Moskalewicz, Sumit Gupta","doi":"10.1093/jnci/djaf024","DOIUrl":"https://doi.org/10.1093/jnci/djaf024","url":null,"abstract":"Background: New highly effective, but expensive, immunotherapies have revolutionized the treatment of relapsed pediatric acute lymphoblastic leukemia (ALL) but their long-term clinical and economic impact is unclear. We developed the ALL Policy microsimulation model to estimate long-term clinical and economic outcomes for patients with pediatric ALL aged 0-17 in Ontario, Canada. We also illustrate the model's clinical utility through a cost-effectiveness analysis of blinatumomab in relapsed B-cell ALL.Methods: The ALL Policy model is informed using health administrative data and chart abstracted data from Ontario, Canada, and published literature. The model estimates lifetime risk of relapse, bone marrow transplant (BMT), conditional life expectancy, quality-adjusted life years (QALY), and total healthcare costs for individuals with pediatric ALL, and can be stratified by relevant clinical characteristics (eg, B-cell or T-cell lineage). Additionally, we subset the model to patients with relapsed B-cell ALL to illustrate use of the model in estimating the cost-effectiveness of blinatumomab vs standard chemotherapy.Results: Simulated pediatric ALL patients diagnosed from 2002-2012 had a projected conditional life expectancy of 64.90 years. The lifetime risk of BMT was estimated at 12.5%. Lifetime healthcare costs were $244,433 CAD (95% CI $213,314, $303,430). Treatment with blinatumomab compared to standard chemotherapy post-relapse was estimated to result in 1.08 additional QALYs and an additional cost of $59,410 CAD (incremental cost-effectiveness ratio of $54,885/QALY).Conclusion: The ALL policy model can serve as a modeling foundation for timely economic evaluation. Introduction of blinatumomab in relapsed B-cell ALL may be a cost-effective strategy.","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Switching between medicare advantage and traditional medicare for individuals newly diagnosed with cancer 2015-2019.

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-13 DOI: 10.1093/jnci/djaf036

Helen M Parsons, Samuel J Greenwald, Stephanie Jarosek, Sayeh Nikpay, Roxanne M Clark, Nathan Shippee, Carrie Henning-Smith, Lindsey Enewold

{"title":"Switching between medicare advantage and traditional medicare for individuals newly diagnosed with cancer 2015-2019.","authors":"Helen M Parsons, Samuel J Greenwald, Stephanie Jarosek, Sayeh Nikpay, Roxanne M Clark, Nathan Shippee, Carrie Henning-Smith, Lindsey Enewold","doi":"10.1093/jnci/djaf036","DOIUrl":"https://doi.org/10.1093/jnci/djaf036","url":null,"abstract":"Background: Medicare Advantage (MA) plans may offer more benefits and lower costs relative to Traditional Medicare (TM), but may also provide narrower provider networks and pre-authorization requirements. We explore the impact of a cancer diagnosis on switching between MA and TM after diagnosis.Methods: We used the 2015-2019 Surveillance, Epidemiology and End Results-Medicare data to examine patterns of switching between MA and TM after cancer relative to those without cancer. We used binomial generalized estimating equations to evaluate the cancer and sociodemographic characteristics of those with higher probabilities of switching.Results: Among those initially enrolled in MA plans (39.27% of those with vs 40.79% without cancer), 3.76% of individuals with cancer switched to TM compared to 2.23% without cancer. For those initially enrolled in TM, 2.96% of individuals with cancer switched to MA vs 4.35% without cancer. Multivariable analyses demonstrated that, among individuals starting in MA, a cancer diagnosis was associated with a 52.02% increase in switching relative to those without cancer, whereas among those starting in TM, a cancer diagnosis was associated with a 26.90% reduction in switching. Younger individuals, males, dual-eligible, those with more comorbidities, rural-dwellers, and those living in zip codes with higher education and income levels also had higher probabilities of switching from MA to TM.Conclusions: Prior to diagnosis, MA enrollment is comparable between individuals with and without cancer. However, after diagnosis, individuals with cancer have higher probability of switching from MA to TM and lower probability of switching from TM to MA.","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration.

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-13 DOI: 10.1093/jnci/djaf037

Joseph R Habib, Ammar A Javed, I Quintus Molenaar, Christopher L Wolfgang, Marc G Besselink

引用次数: 0

Response to kratz, plon, and lupo.

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-11 DOI: 10.1093/jnci/djaf028

Shuai Li, Laura Madanat-Harjuoja, Timothy R Rebbeck, Lisa R Diller

引用次数: 0

Limiting surveillance in individuals with the Palestinian TP53 p. R181C founder variant-is it too soon to draw conclusions?

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-06 DOI: 10.1093/jnci/djaf009

Meis Omran, David Malkin

引用次数: 0

RE: Long-term survival across breslow thickness categories: Findings from a population-based study of 210 042 Australian melanoma patients.

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-06 DOI: 10.1093/jnci/djaf025

Fangzheng Han, Huaimin Liu

引用次数: 0

Response to han and liu.

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-06 DOI: 10.1093/jnci/djaf026

Serigne N Lo, Alexander H R Varey, Sydney Ch'ng, Richard A Scolyer, John F Thompson

引用次数: 0

Re: Childhood, adolescent and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers.

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-05 DOI: 10.1093/jnci/djaf027

Christian P Kratz, Sharon E Plon, Philip J Lupo

引用次数: 0

Changes in time-to-treatment initiation for breast, nonsmall cell lung, Colon, or rectal cancers throughout the COVID-19 pandemic in the United States.

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-03 DOI: 10.1093/jnci/djaf011

Qinjin Fan, Weichuan Dong, Elizabeth J Schafer, Nikita Sandeep Wagle, Jingxuan Zhao, Kewei Sylvia Shi, Xuesong Han, K Robin Yabroff, Leticia M Nogueira

{"title":"Changes in time-to-treatment initiation for breast, nonsmall cell lung, Colon, or rectal cancers throughout the COVID-19 pandemic in the United States.","authors":"Qinjin Fan, Weichuan Dong, Elizabeth J Schafer, Nikita Sandeep Wagle, Jingxuan Zhao, Kewei Sylvia Shi, Xuesong Han, K Robin Yabroff, Leticia M Nogueira","doi":"10.1093/jnci/djaf011","DOIUrl":"https://doi.org/10.1093/jnci/djaf011","url":null,"abstract":"The COVID-19 pandemic disrupted healthcare and reduced cancer diagnoses in the U.S., raising concerns about its impact on time-to-treatment initiation (TTI), a critical factor for survival. This study examined the changes in TTI for 1,213,481 individuals newly diagnosed with female breast, non-small cell lung, colon, or rectal cancer between 2019 and 2022, using the National Cancer Database. We compared TTI in 2020-2022 with 2019 by cancer site, diagnosis time of year, stage, and treatment modality. In 2020, TTI significantly decreased for all cancers compared to 2019, especially in the second quarter (2.97 to 4.29 days). However, TTI increased across sites in 2021 (0.31 to 2.15 days) and in 2022 (1.43 to 5.07 days). Reduced diagnoses and efforts to prioritize cancer care during the pandemic may partly explain observed TTI decreases, whereas workforce constraints likely contributed to the later increases. Ongoing evaluation of TTI and associations with patient outcomes is warranted.","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using GPT-4o to interpret patient-reported outcomes without training.

IF 9.9 1区医学

JNCI Journal of the National Cancer Institute Pub Date : 2025-02-03 DOI: 10.1093/jnci/djaf016

Thomas M Atkinson, Aleksandr Petrov, Kathleen A Lynch, Login S George, Jennifer R Cracchiolo, Bobby Daly, Kristen L Fessele, James H Flory, Jun J Mao, Yuelin Li

引用次数: 0